Castrate-resistant prostate cancer: therapeutic strategies

Bibliography

• Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43(3):408-10
   PubMedGoogle Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM, Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74
   PubMed Web of Science ®Google Scholar
• Galsky MD, Small EJ, Oh WK, Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-46
   PubMedGoogle Scholar
• Rosenberg JE, Galsky MD, Rohs NC, A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106(1):58-62
   PubMedGoogle Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-63
   PubMedGoogle Scholar
• Rosenberg JE, Ryan CJ, Weinberg VK, Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009;27(17):2772-8
   PubMedGoogle Scholar
• Small E, Weinberg VK, Smith DC, Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD Prostate Cancer Clinical Trials Consortium. 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May – 2 June 2009. Proc Am Soc Clin Oncol 2009;27(15S)
   Google Scholar
• Beardsley F, Saad B, Eigl P, A phase II study of patupilone in patients with metastatic castration- resistant prostate cancer who have progressed after docetaxel. J Clin Oncol 2009;27(15S): abstract 5139
   Google Scholar
• Sternberg CN, Whelan P, Hetherington J, Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9
   PubMedGoogle Scholar
• Sternberg CN, Petrylak DP, Sartor O, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-8
   PubMedGoogle Scholar
• George DJ, Halabi S, Shepard TF, Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-6
   PubMedGoogle Scholar
• Reese D, Frohlich M, Bok R, A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAB VEGF) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999;18
   PubMedGoogle Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase 2 study. Eur Urol 2008;54(5):1089-94
   PubMedGoogle Scholar
• Dror Michaelson M, Regan MM, Oh WK, Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20(5):913-20
   PubMedGoogle Scholar
• Sonpavde G, Perriman PO, Bernold D, Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21(2):319-24
   PubMedGoogle Scholar
• Di Lorenzo G, Autorino R, De Laurentiis M, Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6(3):313-7
   PubMedGoogle Scholar
• Mathew P, Logothetis CJ, Dieringer PY, Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2006;5(2):144-9
   PubMedGoogle Scholar
• Romero S, Stanton G, DeFelice J, Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol 2007;25(4):284-90
   PubMedGoogle Scholar
• Mathew P, Tannir N, Tu SM, A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010;65(4):811-5
   PubMedGoogle Scholar
• Petrylak DP. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. Proc Am Soc Clin Oncol 2009;27(15s): abstract 5156
   Google Scholar
• Ryan C, Efstathiou E, Smith M, Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer not exposed to ketoconazole (keto), treated with abiraterone acetate plus prednisone. J Clin Oncol 2009;27(15s):, abstract 5046
   Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
   PubMed Web of Science ®Google Scholar
• Sanda M, Ayyagari SR, Jaffee EM, Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151(3):622-8
   PubMedGoogle Scholar
• Small EJ, Schellhammer PF, Higano CS, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
   PubMed Web of Science ®Google Scholar
• Schellhammer P, Higano C, Berger ER, Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer AUA News, IMPACT study; 2009
   Google Scholar
• Halabi S, Small EJ, Kantoff PW, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232-7
   PubMedGoogle Scholar
• Kaufman HL, Wang W, Manola J, Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122-32
   PubMedGoogle Scholar
• DiPaola RS, Plante M, Kaufman H, A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006;4:1
   PubMed Web of Science ®Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-5
   PubMed Web of Science ®Google Scholar
• Small EJ, Reese DM, Um B, Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5(7):1738-44
   PubMedGoogle Scholar
• Fong L, Kwek SS, O'Brien S, Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69(2):609-15
   PubMedGoogle Scholar
• Reuben J, Lee BN, Li C, Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106(11):2437-44
   PubMedGoogle Scholar
• Slovin S, Beer TM, Higano CS, Initial phase II experience of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009;27(152): abstract 5138
   PubMedGoogle Scholar
• Kojima S, Inahara M, Suzuki H, Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009;16(2):161-7
   PubMedGoogle Scholar
• Higano C, Alumkal J, Ryan CJ, A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer J Clin Oncol 2009;27(15s): abstract 5142
   PubMedGoogle Scholar
• Yin J, Mohammad KS, Kakonen SM, A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003;100(19):10954-9
   PubMed Web of Science ®Google Scholar
• Carducci M, Padley RJ, Breul J, Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-89
   PubMed Web of Science ®Google Scholar
• James N, Caty A, Borre M, Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, Phase 2 trial. Eur Urol 2009;55(5):1112-23
   PubMed Web of Science ®Google Scholar
• Saad F, Hotte SJ, North SA, A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol 2008;26 (20 Suppl): abstract 5002
   Google Scholar
• Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol 2010;28(7):1085-7
   Google Scholar
• Aragon-Ching JB, Ning YM, Chen CC, Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27(2):221-6
   PubMedGoogle Scholar
• Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 2009;14(8):816-27
   PubMedGoogle Scholar